Financial PerformanceFY25 guidance was raised across the board due to higher royalty revenues, API sales, and an increase in partner orders.
Market ExpansionApproval of Darzalex Faspro would mark the first medicine to treat smoldering multiple myeloma, which could significantly expand the market.
Product ApprovalsThe European Commission granted approval to the subcutaneous version of Bristol-Myers Squibb's PD-1 inhibitor, Opdivo, which leverages Halozyme's ENHANZE to enable easier and faster administration.